VNRX · XBRL financial data

VolitionRx financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VNRX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	13	90	306	775	1,234	1,727
Research and development	14,534	15,542	14,573	19,552	14,406	10,081
General and administrative	5,654	8,751	10,938	10,368	8,488	9,464
Total operating expenses	21,261	28,423	32,086	36,763	28,258	23,466
Operating income (loss)	(21,248)	(28,333)	(31,780)	(35,988)	(27,025)	(21,739)
Interest expense	130	156	—	—	—	—
Other income (expense)	0	—	—	311	(233)	(1,765)
Net income (loss)	(20,399)	(26,990)	(30,598)	(35,677)	(27,258)	(23,357)
Earnings per share, diluted USD per share	—	—	—	(0.50)	(0.31)	—
Weighted average shares, diluted thousands of shares	—	—	—	71,235	86,531	106,832

Fiscal years (VNRX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	19,445	20,581	10,867	20,730	3,264	1,117
Accounts receivable	7	13	73	243	111	318
Total current assets	20,332	21,979	12,172	21,854	4,057	2,061
Property and equipment, net	5,171	4,911	5,393	5,523	4,429	4,028
Right-of-use asset	326	384	619	550	600	496
Total assets	26,151	27,490	18,295	27,950	9,400	6,901
Accounts payable	1,540	1,542	3,043	3,211	2,766	2,919
Accrued liabilities	3,492	3,841	2,872	3,929	3,477	4,212
Current portion of long-term debt	841	798	1,067	1,207	860	891
Total current liabilities	6,237	6,516	17,386	31,837	7,791	12,231
Long-term debt	2,607	2,271	2,779	3,625	3,953	5,818
Lease liability, non-current	152	171	400	378	411	277
Total liabilities	9,857	9,768	21,422	36,663	35,507	42,494
Accumulated deficit	(110,174)	(136,989)	(167,257)	(202,577)	(229,544)	(252,901)
Total stockholders' equity	16,294	17,722	(3,127)	(7,802)	(24,908)	(34,246)
Total liabilities and equity	26,151	27,490	18,295	27,950	9,400	6,901
Common shares outstanding (cover page) thousands of shares	52,871	53,775	63,097	82,068	96,544	158,481

Fiscal years (VNRX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(20,399)	(26,990)	(30,598)	(35,677)	(27,258)	(23,357)
Stock-based compensation	—	2,450	0	2,290	1,269	1,740
Net cash from operating activities	(16,464)	(20,854)	(15,278)	(18,063)	(25,894)	(19,683)
Purchases of property and equipment	1,941	974	1,570	1,084	277	90
Net cash from investing activities	(1,648)	(974)	(1,570)	(1,084)	(574)	(90)
Proceeds from issuing common stock	21,197	23,220	6,736	28,388	8,592	11,170
Share repurchases	—	—	0	32	0	—
Proceeds from long-term debt	—	—	1,523	1,855	1,369	1,980
Repayments of long-term debt	—	—	1,268	981	1,088	878
Net cash from financing activities	20,621	22,858	6,938	28,983	8,657	17,093
Net change in cash	2,479	1,137	(9,714)	9,863	(17,466)	(2,147)

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Volitionrx	2,800	399	(5,160)*	13.6M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Gyre Therapeutics	43,287	29,105	(16,728)*	111.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Oncolytics Biotech	4,115	not reported	(8,138)*	127.5M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Seres Therapeutics	15,594	736	(22,394)*	9.9M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Macrogenics	113,907	32,832	(40,748)*	63.7M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Inovio Pharmaceuticals	31,526	0	(18,047)*	103.4M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
XBiotech	109,528	not reported	(4,515)*	30.5M	24.3 quarters	Q2 FY26 10-QJun 30, 2026
Oramed Pharmaceuticals	15,245	not reported	(200)*	41.6M	80.5 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.